Acute Respiratory Distress Syndrome (ARDS) Therapeutics Market
Acute Respiratory Distress Syndrome (ARDS) Therapeutics Market Size, Share &Trends Analysis Report by Drug Class (Vasoconstrictor, Steroids and Antibiotics, Sedative and Paralytic, Surfactant, Bronchodilators, and Others), and by End-User (Hospital/ Clinics and Others) Forecast Period (2023-2029)
Acute respiratory distress syndrome (ARDS) therapeutics market is anticipated to grow at a considerable CAGR of 7.2% during the forecast period. The market for acute respiratory distress syndrome (ARDS) is being driven by factors such as the rising prevalence and incidence of acute lung injury, a wide range of ARDS risk factors, and an increase in the number of patients who have ARDS. The global market for ARDS therapeutics is also expected to grow as a result of factors such as the prevalence of diseases linked to lifestyle choices, air pollution, and accidents that cause ARDS. The incidence rose with patient age, rising from 16 per 100,000 person-years for those aged 15 to 19 to 306 per 100,000 person-years for those aged 75 to 84. Moreover, the growing geriatric population supports market growth. It is expected that the population is more than double and reaches nearly 1.5 billion in 2050. Since the older population is at high risk of getting respiratory and other illnesses, it is expected to generate the need for treatment, thereby driving the market’s growth.
Segmental Outlook
The global acute respiratory distress syndrome (ARDS) therapeutics market is segmented based on the drug class and end-user. Based on the drug class, the market is sub-segmented into vasoconstrictor, steroids and antibiotics, sedative and paralytic, surfactant, bronchodilators, and others. Based on the end-user, the market is sub-segmented into hospital/clinics and others. Among the drug class segment, the surfactant is anticipated to hold a considerable share of the market globally, as ARDS is caused owing to the acute deficiency and inactivation of surfactants which induces alveolar collapse and pulmonary oedema.
Hospital/ Clinics Sub-Segment is Anticipated to Hold a Prominent Share in the Global Acute Respiratory Distress Syndrome (ARDS) Therapeutics Market
Among the end-user, the hospital/ clinic sub-segmented is expected to hold a prominent share of the market during the forecast period. These are well equipped with advanced technological equipment for surgical procedures with improved treatments, owing to which there is a considerable increase in the number of hospital admissions with the ARDS. For instance, according to the Australian Institute of Health and Welfare in May 2022, there were about 11.8 million hospital admission occurred in 2020-21 which is 6.3% more compared to 2019-20. Some other factor supporting the growth of the market includes the increasing number of patient pools along with the launch of new products by the market players are expected to continue over the forecast period, thus, propelling the segmental growth.
Regional Outlooks
The global acute respiratory distress syndrome (ARDS) therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for particular region or country level as per the requirement. Among these, the Asia-Pacific regional market is expected to cater prominent growth over the forecast period, owing to the continuously enhancing healthcare facilities across the nations such as India and others.
Global Acute Respiratory Distress Syndrome (ARDS) Therapeutics Market Growth, by Region 2023-2029
North America is Anticipated to hold a Significant Share of the Global Acute Respiratory Distress Syndrome (ARDS) Therapeutics Market
Among all the regions, North America is anticipated to hold a significant share of the global acute respiratory distress syndrome therapeutics market during the forecast period. The primary factor contributing to the regional market growth includes the increasing government support for R&D activities, well-advanced technological ecosystem, and the growing incidence of acute lung injuries leading to acute respiratory distress syndrome therapeutics is expected to dominate the market. According to the studies published by the National Library of Medicine in February 2022, in the US, the cases of ARDS ranges from 65 to 79 per 100,000 people annually.
Market Players Outlook
The major companies serving the global acute respiratory distress syndrome (ARDS) therapeutics market include Therabron Therapeutics, Inc., Serendex Pharmaceuticals A/S, Silence Therapeutics Plc, Histocell S.L., Altor BioScience Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, the US Food and Drug Administration (FDA) approved several direct biologics to continue with the clinical trial of Landmark Phase 3. The trial will be conducted using its investigation EV drugExoFlow to treat ARDS.
The Report Covers
- Market value data analysis of 2023 and forecast to 2029.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global acute respiratory distress syndrome (ARDS) therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Acute Respiratory Distress Syndrome Therapeutics Market by Drug Class
4.1.1. Vasoconstrictor
4.1.2. Steroids and Antibiotics
4.1.3. Sedative and Paralytic
4.1.4. Surfactant
4.1.5. Bronchodilators
4.1.6. Others
4.2. Global Acute Respiratory Distress Syndrome Therapeutics Market by End-User
4.2.1. Hospitals/ Clinics
4.2.2. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Altor BioScience Corp.
6.2. Athersys, Inc
6.3. Faron Pharmaceuticals Oy
6.4. FirstString Research, Inc.
6.5. FRESENIUS SE & CO. KGAA
6.6. GETINGE AB
6.7. GILEAD SCIENCES INC.
6.8. GlaxoSmithKline Plc
6.9. Histocell S.L.
6.10. Medtronic, Inc.
6.11. NIPRO and PFIZER INC.
6.12. Phylogica Ltd.
6.13. Serendex Pharmaceuticals A/S
6.14. Silence Therapeutics plc
6.15. Terumo Corp.
6.16. Therabron Therapeutics, Inc.
1. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2029 ($ MILLION)
2. GLOBAL VASOCONSTRICTOR FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
3. GLOBAL STEROIDS AND ANTIBIOTICS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
4. GLOBAL SEDATIVE AND PARALYTIC FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
5. GLOBAL SURFACTANT FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
6. GLOBAL BRONCHODILATORS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
7. GLOBAL OTHER DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2029 ($ MILLION)
9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS IN HOSPITALS/ CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS IN OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2029 ($ MILLION)
12. NORTH AMERICAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2029 ($ MILLION)
13. NORTH AMERICAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2029 ($ MILLION)
14. NORTH AMERICAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2029 ($ MILLION)
15. EUROPEAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2029 ($ MILLION)
16. EUROPEAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2029 ($ MILLION)
17. EUROPEAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2029 ($ MILLION)
18. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2029 ($ MILLION)
19. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2029 ($ MILLION)
20. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2029 ($ MILLION)
21. REST OF THE WORLD ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2029 ($ MILLION)
22. REST OF THE WORLD ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2029 ($ MILLION)
23. REST OF THE WORLD ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2029 ($ MILLION)
1. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY DRUG CLASS, 2021 VS 2029 (%)
2. GLOBAL VASOCONSTRICTOR FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
3. GLOBAL STEROIDS AND ANTIBIOTICS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
4. GLOBAL SEDATIVE AND PARALYTIC FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
5. GLOBAL SURFACTANT FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
6. GLOBAL BRONCHODILATORS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
7. GLOBAL OTHER DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY END-USER, 2021 VS 2029 (%)
9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS IN HOSPITALS/ CLINICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS IN OTHER END-USERS MARKET SHARE BY REGION, 2021 VS 2029 (%)
11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SHARE BY REGION, 2021 VS 2029 (%)
12. US ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
13. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
14. UK ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
15. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
16. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
17. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
18. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
19. REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
20. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
21. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
22. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
23. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
24. REST OF ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
25. REST OF THE WORLD ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) THERAPEUTICS MARKET SIZE, 2021-2029 ($ MILLION)
